EFM
SPRY icon

E Fund Management’s ARS Pharmaceuticals SPRY Stock Holding History

E Fund Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Buy
+14,787
New +$142K ﹤0.01% 469

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

E Fund Management's SPRY Position: Q1 2026 in Review

E Fund Management opened a new position in ARS Pharmaceuticals (SPRY) in Q1 2026: 14,787 shares worth $119K. The stake represents ﹤0.01% of the portfolio and ranks #469 among its holdings.

202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • E Fund Management held 14,787 shares of ARS Pharmaceuticals worth $119K as of Q1 2026.
  • ARS Pharmaceuticals was a new E Fund Management position in Q1 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of E Fund Management's portfolio in Q1 2026, its #469 holding.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.